Clinical trials
Observational Spondylitis, Ankylosing trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
14 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2018 | 1 |
| 2021 | 1 |
| 2025 | 4 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 4 |
| Completed | 3 |
| Unknown status | 3 |
| Terminated | 2 |
| Enrolling by invitation | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| China-Japan Friendship Hospital | 3 |
| AbbVie | 1 |
| Charite University, Berlin, Germany | 1 |
| Janssen Research & Development, LLC | 1 |
| Nanfang Hospital, Southern Medical University | 1 |
| Peking Union Medical College Hospital | 1 |
| Peking University People's Hospital | 1 |
| Pfizer | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Sun Yat-sen University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Spondylitis, Ankylosing | 14 |
| Arthritis, Rheumatoid | 3 |
| Arthritis, Psoriatic | 2 |
| Spondylarthritis | 2 |
| Arthritis | 1 |
| Arthritis, Gouty | 1 |
| Arthritis, Juvenile | 1 |
| Autoimmune Diseases | 1 |
| Axial Spondyloarthritis | 1 |
| Giant Cell Arteritis | 1 |
Trials
Showing 1 to 14 of 14. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.